4-Bromo-I(2)-methyl-1H-pyrazole-1-propanol | 1007517-83-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-Bromo-I(2)-methyl-1H-pyrazole-1-propanol
• 英文别名: 3-(4-bromopyrazol-1-yl)-2-methylpropan-1-ol
• CAS: 1007517-83-0
• 化学式: C₇H₁₁BrN₂O
• 分子量: 219.08
• InChiKey: KWRZJYKYIZMUFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS TRYCICLIQUES FUSIONNÉS ET LEURS UTILISATIONS EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020043080A1

  公开（公告）日：2020-03-05

  The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

  本发明涉及一种融合的三环化合物及其在医药中的应用，尤其是作为治疗和/或预防乙型肝炎的药物。具体而言，本发明涉及具有式(I)的化合物或其立体异构体、互变异构体、N-氧化物、溶剂化物、代谢物、药用可接受盐或前药，其中每个变量如说明书中所定义。本发明还涉及将具有式(I)的化合物或其立体异构体、互变异构体、N-氧化物、溶剂化物、代谢物、药用可接受盐或前药作为药物的使用，尤其是作为治疗和/或预防乙型肝炎的药物。
• [EN] NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR TGR5 SOUS FORME D'HÉTÉROARYLES BICYCLIQUES CONTENANT DE L'AZOTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012149236A1

  公开（公告）日：2012-11-01

  Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  公式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中m、Q、T、U、V、环A、X、Y、R3、R4、R4a、R5a、R5b、R5c、R5d、R5e、R6a、R6b和R6c在此定义，提供了TGR5 G蛋白偶联受体调节剂。TGR5 G蛋白偶联受体调节剂在治疗、预防或减缓需要TGR5 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这类新化合物的组合物治疗与TGR5 G蛋白偶联受体活性相关的疾病或症状的方法。
• NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2702042A1

  公开（公告）日：2014-03-05